

The Kohn Lab UCLA
233 posts

@Kohn_Lab
Our mission is to treat patients suffering from primary immunodeficiency diseases with hematopoietic stem cell gene therapy.🩸🦠✂️🧬⛑: tweets from lab members.



The FDA has granted accelerated approval for KRESLADI, a gene therapy for LAD-I — a rare immune disorder that can be fatal in young children. Led by @Kohn_Lab @UCLA, all 9 clinical trial patients survived with restored immune function. 🔗bit.ly/4uVBcfg #GeneTherapy

A blood stem cell gene therapy co-developed by @UCLA's Dr. Donald Kohn restored immune function in 59 of 62 children with ADA-SCID, a rare and fatal immune disorder, with no serious complications reported. #ResearchPowersProgress @Kohn_Lab stemcell.ucla.edu/news/gene-ther…





A new study in @NEJM reports that an investigational gene therapy restored immune function in 9 children with LAD-I, a rare & life-threatening immune disorder. Those children are now living symptom-free 2 years after treatment in clinical trials co-led by @Kohn_Lab @UCLA.


A $14.7M @CIRMnews grant will help Dr. Donald Kohn @Kohn_Lab advance a gene therapy for ADA-SCID toward FDA approval, making this life-saving therapy that has so far successfully treated 48 of 50 children in clinical trials, available to kids everywhere. stemcell.ucla.edu/news/donald-ko…


DNA Contamination Within Recombinant Adeno Associated Virus (AAV) Preparations Correlates with Decreased CD34+ Cell Clonogenic Potential dlvr.it/TD18Bj #MTMCD






To correct the market failures around pediatric #celltherapies and #genetherapies, Crystal Mackall & colleagues propose a new model to lead late-stage development and commercialize these outside of traditional routes in the US. @MackallLab @StanfordMed nature.com/articles/s4159…








